

Circular HSC (SQSD) (NICE) 57/08 TA 139

AN ROINN

Sláinte, Seirbhísí Sóisialta agus Sábháilteachta Poiblí

MÄNNYSTRIE O

Poustie, Resydènter Heisin an Fowk Siccar

Castle Buildings Stormont Estate Belfast BT4 3SQ Tel: 028 9076 5615 Fax: 028 90523206

E-mail: sgu-

niceguidance@dhsspsni.gov.uk

Date: 22 October 2008

Chief Executives of HSS Boards – for distribution to:

Directors of Public Health Directors of Nursing

Directors of Pharmaceutical Services

Directors of Primary Care – for cascade to prescribing and GP Advisors

Chief Executives of HSC Trusts – for distribution to:

Medical Directors – for cascade to relevant staff Directors of Nursing – for cascade to relevant staff

Directors of Pharmaceutical Services – for cascade to relevant

staff

General Practitioners

HSC Clinical and Social Governance Leads

Chief Executives of HSC Special Agencies and NDPBs

For Information

Chairs of HSS Boards
Chairs of HSC Trusts
Chief Executive, Regulation & Quality Improvement Authority
Chief Officers HSC Councils
Chief Executive/Postgraduate Dean, NIMDTA
Chief Executive, NIPPET
Chief Executive, NIPEC
Chief Executive, RMSC

Dear Colleagues

Technology Appraisal No 139 – Continuous Positive Airway Pressure (CPAP) for the Treatment of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS)

Continuous positive airway pressure (CPAP) is recommended as a treatment option for adults with moderate or severe symptomatic obstructive sleep apnoea/hypopnoea syndrome (OSAHS).

CPAP is only recommended as a treatment option for adults with mild OSAHS if:



- They have symptoms that affect their quality of life and ability to go about their daily activities; and
- Lifestyle advice and any other relevant treatment options have been unsuccessful or are considered inappropriate.

The diagnosis and treatment of OSAHS, and the monitoring of the response, should be carried out by a specialist service with appropriately trained medical and support staff.

DHSSPS advises that this appraisal guidance is valid for Northern Ireland and endorses it for implementation in HSC.

The full NICE technology appraisal is available for download at: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11944

The HSC sector also should note that:

- 1. The Department expects HSC organisations to put plans in place within 3 months of the date of issue of this e-mail alert to facilitate the implementation of this guidance;
- 2. This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case;
- 3. NICE has developed tools to help organisations implement this guidance. These are available at http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11944 and include costing tools, implementation advice and audit criteria to monitor local practice.

All NICE guidance endorsed by the Department to date can be accessed on the DHSSPS website at http://www.dhsspsni.gov.uk/sqsd-guidance-nice-guidance

Circular HSS (PPMD) (NICE) 01/006 issued on 30 June 2006 provides further information on the Northern Ireland process for reviewing NICE guidance and further details on the local status of the Institute's guidance. This circular can be accessed at: http://www.dhsspsni.gov.uk/sqsd-guidance-nice-guidance

DR MICHAEL MCBRIDE Chief Medical Officer

Anielra & Intractor